Key Points
- COO sale: Axsome COO Mark Jacobson sold 35,378 shares on Feb. 26 at an average price of $161.88, netting $5,726,990.64, per an SEC filing.
- Mixed fundamentals: Q4 results beat expectations with EPS of ($0.56) vs. ($0.70) and revenue of $196M (up ~65% YoY), but the company remains unprofitable with a negative ROE (232.61%) and a -28.69% net margin, and analysts forecast -2.79 EPS for the fiscal year.
- Market and analyst backdrop: The stock has an $8.38B market cap, a consensus price target of $216.12 (17 Buys, 2 Sells), and high institutional ownership (~81.49%); HC Wainwright is bullish long‑term but trimmed several near‑term 2026 estimates.
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) Director Mark Coleman sold 25,000 shares of the firm's stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $161.11, for a total transaction of $4,027,750.00. Following the transaction, the director directly owned 47,140 shares in the company, valued at $7,594,725.40. The trade was a 34.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Axsome Therapeutics Trading Up 0.4%
Shares of AXSM stock opened at $163.89 on Friday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.50 and a current ratio of 1.55. The company has a market capitalization of $8.38 billion, a price-to-earnings ratio of -44.41 and a beta of 0.40. Axsome Therapeutics, Inc. has a 52-week low of $86.99 and a 52-week high of $191.50. The company has a 50-day simple moving average of $175.78 and a two-hundred day simple moving average of $146.07.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its earnings results on Monday, February 23rd. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.14. The firm had revenue of $196.00 million for the quarter, compared to analysts' expectations of $191.33 million. Axsome Therapeutics had a negative net margin of 28.69% and a negative return on equity of 232.61%. The business's quarterly revenue was up 65.0% on a year-over-year basis. Research analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.
Hedge Funds Weigh In On Axsome Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kemnay Advisory Services Inc. bought a new stake in shares of Axsome Therapeutics during the 4th quarter worth $31,000. Ameriflex Group Inc. bought a new position in Axsome Therapeutics during the 4th quarter worth approximately $37,000. Versant Capital Management Inc grew its holdings in shares of Axsome Therapeutics by 20,300.0% in the third quarter. Versant Capital Management Inc now owns 204 shares of the company's stock worth $25,000 after purchasing an additional 203 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Axsome Therapeutics by 65.4% in the fourth quarter. GAMMA Investing LLC now owns 268 shares of the company's stock valued at $49,000 after acquiring an additional 106 shares during the period. Finally, Farther Finance Advisors LLC grew its stake in shares of Axsome Therapeutics by 602.6% in the fourth quarter. Farther Finance Advisors LLC now owns 274 shares of the company's stock worth $50,000 after purchasing an additional 235 shares during the last quarter. Institutional investors own 81.49% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on the company. Leerink Partners raised their target price on Axsome Therapeutics from $150.00 to $205.00 and gave the company an "outperform" rating in a research report on Wednesday, January 28th. Oppenheimer restated an "outperform" rating and set a $220.00 price target on shares of Axsome Therapeutics in a research report on Wednesday, December 31st. Royal Bank Of Canada raised their price objective on shares of Axsome Therapeutics from $219.00 to $222.00 and gave the stock an "outperform" rating in a report on Tuesday. Cantor Fitzgerald reiterated an "overweight" rating on shares of Axsome Therapeutics in a research note on Wednesday, January 14th. Finally, UBS Group increased their target price on shares of Axsome Therapeutics from $248.00 to $251.00 and gave the company a "buy" rating in a research report on Tuesday. Seventeen research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $216.12.
Check Out Our Latest Report on Axsome Therapeutics
Trending Headlines about Axsome Therapeutics
Here are the key news stories impacting Axsome Therapeutics this week:
- Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $260 price target and forecasts a large rebound into FY‑2027 (FY‑2027 EPS of $11.87 with strong quarterly ramps). This upbeat long‑term view supports investor optimism. Read More.
- Positive Sentiment: Recent company results showed a Q4 EPS beat and revenue up ~65% year‑over‑year, which provides fundamental support for the stock despite near‑term model revisions. Read More.
- Neutral Sentiment: Reported short interest data in late February shows effectively zero shares short (the published figures contain anomalies/NaN), so short‑position dynamics appear minimal and unlikely to be a near‑term driver. Read More.
- Negative Sentiment: HC Wainwright trimmed multiple near‑term 2026 estimates (Q1‑Q3 and FY‑2026 materially lowered; Q4‑2026 also revised down from prior forecasts). These cuts signal more modest near‑term profitability than previously expected and increase uncertainty for 2026 results. Read More.
Axsome Therapeutics Company Profile
(
Get Free Report)
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.
Axsome's pipeline includes several late-stage and approved product candidates.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
